Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. by Vellas, B, Carrillo, M, Sampaio, C, Brashear, H, Siemers, E, Hampel, H, Schneider, L, Weiner, M, Doody, R, Khachaturian, Z, Cedarbaum, J, Grundman, M, Broich, K, Giacobini, E, Dubois, B, Sperling, R, Wilcock, G, Fox, N, Scheltens, P, Touchon, J, Hendrix, S, Andrieu, S, Aisen, P

Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementi... by Sikkes, SA, Visser, P, Knol, D, de Lange-de Klerk, E, Tsolaki, M, Frisoni, G, Nobili, F, Spiru, L, Rigaud, A, Frölich, L, Rikkert, M, Soininen, H, Touchon, J, Wilcock, G, Boada, M, Hampel, H, Bullock, R, Vellas, B, Pijnenburg, Y, Scheltens, P, Verhey, F, Uitdehaag, B

Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. by Visser, P, Verhey, F, Boada, M, Bullock, R, De Deyn, P, Frisoni, G, Frolich, L, Hampel, H, Jolles, J, Jones, R, Minthon, L, Nobili, F, Olde Rikkert, M, Ousset, P, Rigaud, A, Scheltens, P, Soininen, H, Spiru, L, Touchon, J, Tsolaki, M, Vellas, B, Wahlund, L, Wilcock, G, Winblad, B